Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy

The Southern African HIV Clinicians Society would like to update all HIV-treating clinicians with regard to the use of dolutegravir in women of childbearing potential (WOCPP).

In preliminary data from the Tsepamo study in Botswana, it was found that 0.94% (95% confidence interval [CI]: 0.37 – 2.4) of babies (4/426) born to women who were taking dolutegravir periconception had neural tube defects (NTDs), compared with 0.1% of babies (14/11 173) of women taking other antiretroviral drugs (ARVs) in the periconception period.1 No NTDs were observed in pregnancies where dolutegravir was initiated later in pregnancy. Further data from the Tsepamo study were presented at AIDS 2018: the updated number of NTDs with periconception dolutegravir exposure in the Tsepamo cohort is 4/996, 0.67% (95% CI: 0.26 to 1.7). The next formal analysis will occur after 31 March 2019 and will include women exposed to dolutegravir from conception before the recent change in guidance. Tsepamo plans to expand the number of study sites, increasing the coverage from 45% to 72% of births in Botswana with a projected denominator of over 1200 by March 2019.1

Prior to the data from Botswana, reproductive toxicology studies had not shown any concerning findings. To date, other data on the use of dolutegravir in pregnancy, including data from the Antiretroviral Pregnancy Registry, clinical trials and post-marketing surveillance, have not indicated a risk of NTDs.

The World Health Organization (WHO) launched new interim guidance on HIV treatment at AIDS 2018, recommending dolutegravir for everyone aged six years and above. Based on limited data, WHO notes that there are safety concerns regarding the use of dolutegravir periconception.2

World Health Organization recommendations for WOCPP include the following:

- Dolutegravir-based first-line antiretroviral therapy (ART) is recommended for:
  - all pregnant (from eight weeks after conception) and breastfeeding women and adolescent girls;2
  - women and adolescent girls with effective contraception or not of childbearing potential.
  - Women and adolescent girls of childbearing potential who want to become pregnant or have
    - Consider the balance of benefits and risks, including fertility levels, contraceptive availability
    - Strengthen the integration of sexual and reproductive health services within HIV treatment
    - A woman-centred approach should be adopted: healthcare providers should provide women

Southern African HIV Clinicians Society guidance

- A woman-centred approach should be adopted: healthcare providers should give women

Dates: Received: 20 Sept. 2018 | Accepted: 20 Sept. 2018 | Published: 17 Oct. 2018
Copyright: © 2018. The Authors. Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.
• Dolutegravir-based first-line ART is recommended for:
  • all pregnant (from eight weeks after conception) and breastfeeding women and adolescent girls
  • women and adolescent girls on effective contraception or not of childbearing potential.
• Women and adolescent girls of childbearing potential who want to become pregnant or have no effective contraception should be adequately counselled about the potential risks and benefits of dolutegravir- versus efavirenz-based ART and should be offered the choice of both treatments. This discussion should be documented, preferably along with consent from those women opting for dolutegravir-based ART.
• If pregnancy is confirmed in the first eight weeks while a woman is taking dolutegravir, she should be adequately counselled about the potential risks and benefits of dolutegravir- versus efavirenz-based ART and should offered the choice of both treatments. This discussion should be documented, preferably along with consent from those women opting for dolutegravir-based ART. The risk and benefits of switching during pregnancy should also be discussed. Switching is associated with a small risk of viraemia in a previously virologically suppressed patient, which may result in risk of mother-to-child transmission and resistance.

While this is an early signal, it warrants careful pharmacovigilance and further evaluation. As more information becomes available, we will update our guidance.

References